Fluidigm Raises $5M


South San Francisco, CA-based Fluidigm, which makes instruments for measuring gene expression in single cells such as tumor cells, has raised $5 million in an offering of debt, options, and securities, according to a January 20 regulatory filing. The firm may have needed the funds to tide it over on its way to a planned initial public offering; the company restarted the paperwork for its IPO just last month, after abandoning plans to go public in 2008.

Wade Roush is Xconomy's chief correspondent and editor of Xconomy San Francisco. You can subscribe to his Google Group or e-mail him at wroush@xconomy.com. Follow @

By posting a comment, you agree to our terms and conditions.